[1] Saracíbar-Razquin M, Zaragoza-Salcedo A, Martín-Martín J, et al. Development of a scale to gain insight into the experience of living with chronic heart failure: The UNAV-Experience of Living with Chronic Heart Failure Scale. An Sist Sanit Navar.2024 Apr 16;47(1):e1071.
[2] Trochu JN. Chronic heart failure with reduced EF: A decade of major pharmacological innovations. Presse Med.2024 Mar;53(1):104219.
[3] Bhatt AS, Vaduganathan M, Claggett BL, et al. Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure Management. JAMA Cardiol.2023 Nov 1;8(11):1041-1048.
[4] 赖呈哲. 沙库巴曲缬沙坦治疗老年慢性心力衰竭合并糖尿病的临床效果观察[J].心血管病防治知识, 2022, 12(18):4-7.
[5] 贾晓艳,刘永铭.SGLT2i在射血分数保留心力衰竭中的作用研究进展[J].解放军医学杂志,2022,47(2):203-212.
[6] 中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心力衰竭和心肌病杂志(中英文),2018,2(4):196-225.
[7] 张维,张先林,康品方,等.沙库巴曲缬沙坦治疗老年心力衰竭的疗效及其对血清学指标的影响[J].临床心血管病杂志, 2019, 35(12):1145-1148.
[8] Chen J, Jiang C, Guo M, et al. Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis. Cardiovasc Diabetol.2024 Jan 3;23(1):2.
[9] Shi L, Zhang Y, Zhang J, et al. Application of blood pre-albumin and NT-pro BNP levels in evaluating prognosis of elderly chronic heart failure patients. Exp Ther Med.2020 Aug;20(2):1337-1342.
[10] 卜星彭,李春霞,李丽,等. 达格列净对老年射血分数保留的心力衰竭的疗效观察[J]. 中华老年心脑血管病杂志,2022,24(7):689-692.
[11] 陈学锋,容春莉,姚文静,等. 钠-葡萄糖共转运蛋白2抑制剂相关心血管获益机制的研究进展[J]. 中国全科医学,2021,24(3):272-279.
[12] 郝正阳,张彦周. 血清sST2水平对服用沙库巴曲缬沙坦的慢性HFrEF患者1a内再入院的预测价值[J]. 郑州大学学报(医学版),2022,57(4):582-585.
[13] Li M, Duan L, Cai Y, et al. Prognostic value of soluble suppression of tumorigenesis-2 (sST2) for cardiovascular events in coronary artery disease patients with and without diabetes mellitus. Cardiovasc Diabetol.2021 Feb 19;20(1):49.
[14] 戴日新,刘露佳,杨锡恒,等. 达格列净在合并2型糖尿病的射血分数中间值心力衰竭患者中的研究[J]. 实用医学杂志,2020,36(18):2505-2509.
[15] Bendotti G, Montefusco L, Pastore I, et al. The anti-inflammatory and immunological properties of SGLT-2 inhibitors. J Endocrinol Invest.2023 Dec;46(12):2445-2452.
[16] Barsukov AV, Seidova AY, Shcherbakova KA, et al. Systemic Action of Inflammatory Mediators in Patients with Essential Hypertension and Diastolic Chronic Heart Failure: A Clinical Pathophysiological Study. Pathophysiology.2020 Dec 12;27(1):30-43.
[17] Bonnet F, Scheen AJ. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease. Diabetes Metab.2018 Dec;44(6):457-464.
[18] Garvey WT, Van Gaal L, Leiter LA, et al. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism.2018 Aug;85:32-37. |
